-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Kymera Therapeutics, Raises Price Target to $60

Benzinga·02/28/2025 12:43:19
Listen to the news
HC Wainwright & Co. analyst Andrew Fein maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $54 to $60.